glp-1 bone loss The Impact of GLP1 Agonists on Metabolism: A Systematic Review Study reveals exercise and GLP-1

Q2 2025 Snapshot Eli Lilly and Company dominates the US 57 % GLP-1 share, led by Mounjaro (tirzepatide) HCP & Zepbound (tirzepatide) HCP Novo Nordisk rules Europe 63 % value share, powered by Wegovy(semaglutide) injection 2.4 mg HCP & Ozempic APAC & Emerging Markets are the next frontier (+1113 % YoY) Together, they crossed $24 Billion in H1 2025 GLP-1 revenue proving the real blockbuster of this decade isnt oncology or immunology Its metabolic health

For a detailed peptide-by-peptide account and vote explanation, see FDA Peptide Compounding Vote 2026: What the Recommendation Means for Patients

Beyond postinjury recovery, these peptides may serve a role in prehabilitationhelping patients optimize muscle mass, tissue resilience, and joint function before surgery

3 (download XLSX Numerical data for GSH calibration curve

When the gut mucosa is irritated, injured, or inflamed, the mucosal enterocytes release alarm molecules which reduce the expression of tolerance signals and promote the release of pro-inflammatory signals that disrupt the gut barrier